Ziyad Al-Aly MD
@zalaly.bsky.social
📤 17414
📥 1
📝 54
Physician | Scientist | working on Long Covid
The finding that stopping GLP-1 drugs can undo years of heart protection is resonating. Coverage from CNN, TIME, USA Today, CNBC, Gizmodo, and others. What 3 years of continuous treatment builds, ~1.5 years off the drug can erase.
3 months ago
1
21
4
What happens to the heart when people stop GLP-1 drugs? The short answer: nothing good. 333,000+ adults. 3 years. 16 treatment scenarios. New in
@bmjmedicine.bsky.social
đź§µ
3 months ago
2
70
39
I joined Dr. Susan Kuo from
@longcovidcan-co.bsky.social
to talk about Long COVID — what we've learned, where we are, and what's ahead.
youtu.be/T3WD-tTFSWQ
loading . . .
Long Covid: Past, Present and Future – ft. Dr. Ziyad Al-Aly
YouTube video by Canadian Covid Society
https://youtu.be/T3WD-tTFSWQ
3 months ago
2
48
17
For your weekend reading: I wrote about what our BMJ findings mean for addiction — why GLP-1s work across every addictive substance, and how these drugs seem to quiet cravings the same way they quiet food noise.
@us.theconversation.com
theconversation.com/glp-1-drugs-...
loading . . .
GLP-1 drugs may fight addiction across every major substance, according to a study of 600,000 people
GLP-1 drugs are the first medication to show promise for treating addiction to a wide range of substances.
https://theconversation.com/glp-1-drugs-may-fight-addiction-across-every-major-substance-according-to-a-study-of-600-000-people-275233
3 months ago
1
30
12
New in the BMJ: Our study of 600,000 people found GLP-1 drugs associated with 50% fewer substance-related deaths, 39% fewer overdoses, and reduced addiction risk across alcohol, opioids, cocaine, cannabis, and nicotine.
www.bmj.com/content/392/...
loading . . .
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
Objectives To investigate whether initiation of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with both reduced risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and ot...
https://www.bmj.com/content/392/bmj-2025-086886
3 months ago
1
125
50
Please help us spread the word. We are hiring postdoctoral fellows in Clinical Epidemiology and Pharmacoepidemiology. Details and application via Indeed.
loading . . .
Postdoctoral Fellow - St. Louis, MO 63106 - Indeed.com
Veterans Research and Education Foundation of St. Louis
https://www.indeed.com/job/postdoctoral-fellow-aee811b987bd97d7
5 months ago
0
15
15
Honored to speak at Harvard’s Radcliffe Institute workshop on
#LongCOVID
. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing forward!!!
about 1 year ago
12
152
20
For decades, the junk food industry has deliberately engineered foods to be addictive. GLP-1 drugs have helped people break free from this cycle. The industry is now searching for ways to undo the effects of these meds, aiming to design foods that remain addictive for those on GLP1.
buff.ly/40QHDnk
loading . . .
Ozempic Could Crush the Junk Food Industry. But It Is Fighting Back.
As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.
https://www.nytimes.com/2024/11/19/magazine/ozempic-junk-food.html
over 1 year ago
7
131
62
GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction.
loading . . .
Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine
An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic…
https://buff.ly/4jm6iqC
over 1 year ago
1
49
12
New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics. Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues.
www.nordforsk.org/2025/knowled...
over 1 year ago
0
95
32
Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris.
@theconversation.com
@france.theconversation.com
theconversation.com/alzheimer-ad...
loading . . .
Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés
Les médicaments GLP-1 sont efficaces pour traiter le diabète et l’obésité. Ils pourraient l’être aussi pour lutter contre de nombreuses autres affections. Néanmoins, des effets indésirables existent.
https://theconversation.com/alzheimer-addictions-depression-les-effets-benefiques-de-lozempic-et-des-medicaments-apparentes-248152
over 1 year ago
0
24
6
I talked to Dani Blum from
@nytimes.com
about the potential role of GLP-1 drugs (Ozepmic and similar drugs) on Alzheimer’s disease. They seem promising, but more data is needed.
www.nytimes.com/2025/01/31/w...
loading . . .
Could Ozempic Protect Against Alzheimer’s?
Could a diabetes and weight loss drug benefit the brain? Here’s what scientists are learning.
https://www.nytimes.com/2025/01/31/well/mind/ozempic-alzheimers.html
over 1 year ago
3
27
3
🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions.
www.nature.com/articles/s41...
loading . . .
Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine
An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medicat...
https://www.nature.com/articles/s41591-024-03412-w
over 1 year ago
2
55
13
đź“„ Free access to the full study:
rdcu.be/d6VYU
New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (e.g. Ozempic and similar weight loss drugs) across 175 health conditions. Please share and download before it goes back behind paywall.
loading . . .
Mapping the effectiveness and risks of GLP-1 receptor agonists
Nature Medicine - An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other...
https://rdcu.be/d6VYU
over 1 year ago
5
66
22
The latest from my team in Nature Medicine. We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me A đź§µ
www.nature.com/articles/s41...
loading . . .
Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine
An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medicat...
https://www.nature.com/articles/s41591-024-03412-w
over 1 year ago
15
213
68
My first post has to be about
#LongCOVID
🔹 400 million individuals affected worldwide 🔹 $1 trillion in annual economic costs 🔹 Countless lives & communities shattered The time for a comprehensive policy and research response is now! Details in our review here
www.nature.com/articles/s41...
loading . . .
Long COVID science, research and policy - Nature Medicine
This Review outlines the current state of scientific evidence on long COVID, discusses its impacts on patients, health systems, economies and global health metrics, and proposes a forward-looking rese...
https://www.nature.com/articles/s41591-024-03173-6
over 1 year ago
107
1619
756
you reached the end!!
feeds!
log in